Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy’s developer, Oncopeptides,…